Analysts Set argenx SE (NASDAQ:ARGX) PT at $547.74

Shares of argenx SE (NASDAQ:ARGX) have earned a consensus recommendation of “Moderate Buy” from the twenty-two research firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $547.74.

A number of equities analysts have recently commented on ARGX shares. Morgan Stanley lowered their price target on argenx from $515.00 to $510.00 and set an “overweight” rating for the company in a report on Tuesday, May 28th. JPMorgan Chase & Co. boosted their price target on argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Wedbush boosted their price target on argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a report on Friday, July 26th. Stifel Nicolaus boosted their price target on argenx from $485.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Finally, Evercore ISI boosted their price target on argenx from $478.00 to $533.00 and gave the stock an “outperform” rating in a report on Friday, July 12th.

Institutional Investors Weigh In On argenx

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Profund Advisors LLC boosted its position in shares of argenx by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock valued at $418,000 after purchasing an additional 28 shares in the last quarter. Wealth Alliance boosted its position in shares of argenx by 4.8% during the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after purchasing an additional 29 shares in the last quarter. Lindbrook Capital LLC boosted its position in shares of argenx by 23.1% during the 1st quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock valued at $78,000 after purchasing an additional 37 shares in the last quarter. Wahed Invest LLC boosted its position in shares of argenx by 9.6% during the 4th quarter. Wahed Invest LLC now owns 457 shares of the company’s stock valued at $174,000 after purchasing an additional 40 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Price Performance

ARGX opened at $537.94 on Friday. The business has a fifty day simple moving average of $505.20 and a 200 day simple moving average of $428.02. The company has a market capitalization of $32.17 billion, a PE ratio of -95.04 and a beta of 0.62. argenx has a 1 year low of $327.73 and a 1 year high of $554.74.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. The firm had revenue of $489.43 million during the quarter, compared to the consensus estimate of $436.66 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same period in the prior year, the company posted ($1.69) EPS. Equities analysts anticipate that argenx will post -0.37 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.